Arovella licences novel monoclonal antibody from MD Anderson
Filed with ASX · · 32 pages · English
Arovella Therapeutics Limited on 6ix
In the deck
Earlier from Arovella Therapeutics
- Chile Ministry of Health Approval Granted for ZolpiMist
- GM presentation
- Dr Reuben Benjamin Appointed to SUDA iNKT Cell Therapy SAB
- SUDA signs Licence and Distribution Agreement with STADA
- ZolpiMist Update
Later from Arovella Therapeutics
- AGM FY21 Presentation
- Arovella Completes $4.57M Placement & Launches $1.5M SPP
- SPP Offer Booklet
- Investor Presentation
- Arovella SPP Closed early over subscribed
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics